RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary

Journal of Pathology

Volumn 229, Issue 3, 2013, Pages 469-476

  Ryland, Georgina L ^a,b   Hunter, Sally M ^a   Doyle, Maria A ^a   Rowley, Simone M ^a   Christie, Michael ^c   Allan, Prue E ^a   Bowtell, David Dl ^d,e   Gorringe, Kylie L ^a,d   Campbell, Ian G ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Australian Ovarian Cancer Study Group   (Australia)

Author keywords

DNA sequencing; mucinous ovarian cancer; RNF43; somatic mutation

Indexed keywords

ALLELISM; ARTICLE; COLLOID CARCINOMA; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; MUTATION RATE; NUCLEOTIDE SEQUENCE; ONCOGENE RNF43; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; COMPUTER SIMULATION; CYSTADENOMA, MUCINOUS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DNA-BINDING PROTEINS; EXOME; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, MOLECULAR; MUTATION; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84872931911     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4134     Document Type: Article

References (46)

1. Seidman JD, Kurman RJ, Ronnett BM,. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27: 985-993. (Pubitemid 36763545)
2. Seidman JD, Horkayne-Szakaly I, Haiba M, et al,. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23: 41-44. (Pubitemid 38018236)
3. Shimada M, Kigawa J, Ohishi Y, et al,. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 2009; 113: 331-334.
4. Frumovitz M, Schmeler KM, Malpica A, et al,. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol 2010; 117: 491-496.
5. Hess V, A'Hern R, Nasiri N, et al,. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044. (Pubitemid 41095036)
6. Zaino RJ, Brady MF, Lele SM, et al,. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 2011; 117: 554-562.
7. Mok SC, Bell DA, Knapp RC, et al,. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489-1492. (Pubitemid 23113216)
8. Puls LE, Powell DE, DePriest PD, et al,. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992; 47: 53-57.
9. Riopel MA, Ronnett BM, Kurman RJ,. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999; 23: 617-635. (Pubitemid 29262825)
10. Cuatrecasas M, Villanueva A, Matias-Guiu X, et al,. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997; 79: 1581-1586. (Pubitemid 27154791)
11. Hunter SM, Gorringe KL, Christie M, et al,. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res 2012; 18: 5267-5277.
12. McAlpine JN, Wiegand KC, Vang R, et al,. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009; 9: 433.
13. Lee KR, Young RH,. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003; 27: 281-292. (Pubitemid 36245793)
14. Sugiura T, Yamaguchi A, Miyamoto K,. A cancer-associated RING finger protein, RNF43, is a ubiquitin ligase that interacts with a nuclear protein, HAP95. Exp Cell Res 2008; 314: 1519-1528.
15. Yagyu R, Furukawa Y, Lin YM, et al,. A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer. Int J Oncol 2004; 25: 1343-1348.
16. Takemasa I, Higuchi H, Yamamoto H, et al,. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. Biochem Biophys Res Commun 2001; 285: 1244-1249. (Pubitemid 32912916)
17. Wu J, Jiao Y, Dal Molin M, et al,. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 2011; 108: 21188-21193.
18. Furukawa T, Kuboki Y, Tanji E, et al,. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011; 1: 161.
19. Bryan EJ, Watson RH, Davis M, et al,. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res 1996; 56: 719-721. (Pubitemid 26055458)
20. Merritt MA, Green AC, Nagle CM, et al,. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008; 122: 170-176. (Pubitemid 350209992)
21. Rozen S, Skaletsky H,. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-386.
22. Desmet FO, Hamroun D, Lalande M, et al,. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009; 37: e67.
23. Adzhubei IA, Schmidt S, Peshkin L, et al,. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
24. Ferrer-Costa C, Gelpi JL, Zamakola L, et al,. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 2005; 21: 3176-3178. (Pubitemid 41418475)
25. Li B, Krishnan VG, Mort ME, et al,. Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 2009; 25: 2744-2750.
26. Schwarz JM, Rodelsperger C, Schuelke M, et al,. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575-576.
27. Calabrese R, Capriotti E, Fariselli P, et al,. Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat 2009; 30: 1237-1244.
28. Thusberg J, Olatubosun A, Vihinen M,. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 2011; 32: 358-368.
29. Weinberg RA,. Tumor suppressor genes. Science 1991; 254: 1138-1146. (Pubitemid 21917438)
30. Gorringe KL, Ramakrishna M, Williams LH, et al,. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer 2009; 48: 931-942.
31. Pieretti M, Hopenhayn-Rich C, Khattar NH, et al,. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002; 20: 11-23. (Pubitemid 34151056)
32. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
33. Jones S, Wang TL, Shih Ie M, et al,. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
34. Wiegand KC, Shah SP, Al-Agha OM, et al,. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
35. Shih I, Panuganti PK, Kuo KT, et al,. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 2011; 178: 1442-1447.
36. McConechy MK, Anglesio MS, Kalloger SE, et al,. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011; 223: 567-573.
37. Kelemen LE, Kobel M,. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 2011; 12: 1071-1080.
38. Ong CK, Subimerb C, Pairojkul C, et al,. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012; 44: 690-693.
39. Nakanuma Y, Zen Y, Harada K, et al,. Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach. J Hepatobil Pancreat Sci 2010; 17: 211-222.
40. Yonezawa S, Higashi M, Yamada N, et al,. Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobil Pancreat Sci 2010; 17: 108-124.
41. Shibahara H, Tamada S, Goto M, et al,. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol 2004; 28: 327-338. (Pubitemid 38269566)
42. Zen Y, Fujii T, Itatsu K, et al,. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006; 44: 1333-1343. (Pubitemid 44748384)
43. Nakanuma Y, Sato Y,. Cystic and papillary neoplasm involving peribiliary glands: a biliary counterpart of branch-type intraductal papillary mucinous cystic neoplasm? Hepatology 2012; 55: 2040-2041.
44. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
45. Hao HX, Xie Y, Zhang Y, et al,. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012; 485: 195-200.
46. Cerami E, Gao J, Dogrusoz U, et al,. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.